The Fbxw7/hCdc4 tumor suppressor in human cancer

Cancer Letters

Volumn 271, Issue 1, 2008, Pages 1-12

  Tan, YingMeei ^a   Sangfelt, Olle ^b   Spruck, Charles ^a  

^a SIDNEY KIMMEL CANCER CENTER   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

c Myc; Cyclin E1; Fbxw7; Tumor suppressor; Ubiquitin ligase

Indexed keywords

AURORA A KINASE; CYCLIN E1; F BOX PROTEIN; GLYCOGEN SYNTHASE KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MYC PROTEIN; NOTCH RECEPTOR; NOTCH4 RECEPTOR; ONCOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PRESENILIN; PROTEIN C JUN; PROTEIN FBXW7; PROTEIN HCDC4; PROTEIN P53; STEROL REGULATORY ELEMENT BINDING PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; FBXW7 GENE; GENE MUTATION; GENETIC STABILITY; HCDC4 GENE; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FAMILY; SHORT SURVEY; TUMOR SUPPRESSOR GENE; UBIQUITINATION;

EID: 53049097854     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.04.036     Document Type: Review

References (97)

1. Bashir T., and Pagano M. Aberrant ubiquitin-mediated proteolysis of cell cycle regulatory proteins and oncogenesis. Adv. Cancer Res. 88 (2003) 101-144
2. Castro A., Bernis C., Vigneron S., Labbe J.C., and Lorca T. The anaphase-promoting complex: a key factor in the regulation of cell cycle. Oncogene 24 (2005) 314-325
3. Harper J.W., Burton J.L., and Solomon M.J. The anaphase-promoting complex: it's not just for mitosis any more. Genes Dev. 16 (2002) 2179-2206
4. Cenciarelli C., Chiaur D.S., Guardavaccaro D., Parks W., Vidal M., and Pagano M. Identification of a family of human F-box proteins. Curr. Biol. 9 (1999) 1177-1179
5. Kipreos E.T., and Pagano M. The F-box protein family. Genome Biol. 1 (2000) REVIEWS3002
6. Spruck C.H., et al. hCDC4 gene mutations in endometrial cancer. Cancer Res. 62 (2002) 4535-4539
7. Bai C., Sen P., Hofmann K., Ma L., Goebl M., Harper J.W., and Elledge S.J. SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box. Cell 86 (1996) 263-274
8. Zhang W., and Koepp D.M. Fbw7 isoform interaction contributes to cyclin E proteolysis. Mol. Cancer Res. 4 (2006) 935-943
9. Orlicky S., Tang X., Willems A., Tyers M., and Sicheri F. Structural basis for phosphodependent substrate selection and orientation by the SCFCdc4 ubiquitin ligase. Cell 112 (2003) 243-256
10. Welcker M., Orian A., Grim J.E., Eisenman R.N., and Clurman B.E. A nucleolar isoform of the Fbw7 ubiquitin ligase regulates c-Myc and cell size. Curr. Biol. 14 (2004) 1852-1857
11. Nash P., et al. Multisite phosphorylation of a CDK inhibitor sets a threshold for the onset of DNA replication. Nature 414 (2001) 514-521
12. Hao B., Oehlmann S., Sowa M.E., Harper J.W., and Pavletich N.P. Structure of a Fbw7-Skp1-cyclin E complex: multisite-phosphorylated substrate recognition by SCF ubiquitin ligases. Mol. Cell 26 (2007) 131-143
13. Hartwell L.H., Mortimer R.K., Culotti J., and Culotti M. Genetic control of the cell division cycle in yeast: V. Genetic analysis of cdc mutants. Genetics 74 (1973) 267-286
14. Henchoz S., Chi Y., Catarin B., Herskowitz I., Deshaies R.J., and Peter M. Phosphorylation- and ubiquitin-dependent degradation of the cyclin-dependent kinase inhibitor Far1p in budding yeast. Genes Dev. 11 (1997) 3046-3060
15. Jackson L.P., Reed S.I., and Haase S.B. Distinct mechanisms control the stability of the related S-phase cyclins Clb5 and Clb6. Mol. Cell. Biol. 26 (2006) 2456-2466
16. Perkins G., Drury L.S., and Diffley J.F. Separate SCF(CDC4) recognition elements target Cdc6 for proteolysis in S phase and mitosis. EMBO J. 20 (2001) 4836-4845
17. Winston J.T., Chu C., and Harper J.W. Culprits in the degradation of cyclin E apprehended. Genes Dev. 13 (1999) 2751-2757
18. Spruck C.H., Won K.A., and Reed S.I. Deregulated cyclin E induces chromosome instability. Nature 401 (1999) 297-300
19. Bortner D.M., and Rosenberg M.P. Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. Mol. Cell. Biol. 17 (1997) 453-459
20. Donnellan R., and Chetty R. Cyclin E in human cancers. FASEB J. 13 (1999) 773-780
21. Koepp D.M., Schaefer L.K., Ye X., Keyomarsi K., Chu C., Harper J.W., and Elledge S.J. Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science 294 (2001) 173-177
22. Moberg K.H., Bell D.W., Wahrer D.C., Haber D.A., and Hariharan I.K. Archipelago regulates Cyclin E levels in Drosophila and is mutated in human cancer cell lines. Nature 413 (2001) 311-316
23. Strohmaier H., Spruck C.H., Kaiser P., Won K.A., Sangfelt O., and Reed S.I. Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 413 (2001) 316-322
24. Clurman B.E., Sheaff R.J., Thress K., Groudine M., and Roberts J.M. Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev. 10 (1996) 1979-1990
25. Welcker M., Singer J., Loeb K.R., Grim J., Bloecher A., Gurien-West M., Clurman B.E., and Roberts J.M. Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation. Mol. Cell 12 (2003) 381-392
26. Won K.A., and Reed S.I. Activation of cyclin E/CDK2 is coupled to site-specific autophosphorylation and ubiquitin-dependent degradation of cyclin E. EMBO J. 15 (1996) 4182-4193
27. Ye X., et al. Recognition of phosphodegron motifs in human cyclin E by the SCF(Fbw7) ubiquitin ligase. J. Biol. Chem. 279 (2004) 50110-50119
28. van Drogen F., Sangfelt O., Malyukova A., Matskova L., Yeh E., Means A.R., and Reed S.I. Ubiquitylation of cyclin E requires the sequential function of SCF complexes containing distinct hCdc4 isoforms. Mol. Cell 23 (2006) 37-48
29. Amati B., Brooks M.W., Levy N., Littlewood T.D., Evan G.I., and Land H. Oncogenic activity of the c-Myc protein requires dimerization with Max. Cell 72 (1993) 233-245
30. Amati B., Littlewood T.D., Evan G.I., and Land H. The c-Myc protein induces cell cycle progression and apoptosis through dimerization with Max. EMBO J. 12 (1993) 5083-5087
31. Cole M.D. The myc oncogene: its role in transformation and differentiation. Annu. Rev. Genet. 20 (1986) 361-384
32. Coller H.A., Grandori C., Tamayo P., Colbert T., Lander E.S., Eisenman R.N., and Golub T.R. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc. Natl. Acad. Sci. USA 97 (2000) 3260-3265
33. Coppola J.A., and Cole M.D. Constitutive c-myc oncogene expression blocks mouse erythroleukaemia cell differentiation but not commitment. Nature 320 (1986) 760-763
34. Evan G.I., et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 69 (1992) 119-128
35. Solomon D.L., Amati B., and Land H. Distinct DNA binding preferences for the c-Myc/Max and Max/Max dimers. Nucleic Acids Res. 21 (1993) 5372-5376
36. Adhikary S., and Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat. Rev. Mol. Cell Biol. 6 (2005) 635-645
37. Dalla-Favera R., Bregni M., Erikson J., Patterson D., Gallo R.C., and Croce C.M. Human c-myc oncogene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc. Natl. Acad. Sci. USA 79 (1982) 7824-7827
38. Dalla-Favera R., Martinotti S., Gallo R.C., Erikson J., and Croce C.M. Translocation and rearrangements of the c-myc oncogene locus in human undifferentiated B-cell lymphomas. Science 219 (1983) 963-967
39. Pelengaris S., Khan M., and Evan G. c-MYC: more than just a matter of life and death. Nat. Rev. Cancer 2 (2002) 764-776
40. Yeh E., et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat. Cell Biol. 6 (2004) 308-318
41. Sears R., Nuckolls F., Haura E., Taya Y., Tamai K., and Nevins J.R. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 14 (2000) 2501-2514
42. Sjostrom S.K., Finn G., Hahn W.C., Rowitch D.H., and Kenney A.M. The Cdk1 complex plays a prime role in regulating N-myc phosphorylation and turnover in neural precursors. Dev. Cell 9 (2005) 327-338
43. Shaulian E., and Karin M. AP-1 as a regulator of cell life and death. Nat. Cell Biol. 4 (2002) E131-E136
44. Wisdom R., Johnson R.S., and Moore C. c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms. EMBO J. 18 (1999) 188-197
45. Nateri A.S., Riera-Sans L., Da Costa C., and Behrens A. The ubiquitin ligase SCFFbw7 antagonizes apoptotic JNK signaling. Science 303 (2004) 1374-1378
46. 2-terminal kinases target the ubiquitination of their associated transcription factors. J. Biol. Chem. 272 (1997) 32163-32168
47. Musti A.M., Treier M., and Bohmann D. Reduced ubiquitin-dependent degradation of c-Jun after phosphorylation by MAP kinases. Science 275 (1997) 400-4002
48. Wei W., Jin J., Schlisio S., Harper J.W., and Kaelin Jr. W.G. The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell 8 (2005) 25-33
49. Hubbard E.J., Wu G., Kitajewski J., and Greenwald I. Sel-10, a negative regulator of lin-12 activity in Caenorhabditis elegans, encodes a member of the CDC4 family of proteins. Genes Dev. 11 (1997) 3182-3193
50. Itoh M., et al. Mind bomb is a ubiquitin ligase that is essential for efficient activation of Notch signaling by Delta. Dev. Cell 4 (2003) 67-82
51. Qiu L., et al. Recognition and ubiquitination of Notch by Itch, a hect-type E3 ubiquitin ligase. J. Biol. Chem. 275 (2000) 35734-35737
52. Tsunematsu R., et al. Mouse Fbw7/Sel-10/Cdc4 is required for notch degradation during vascular development. J. Biol. Chem. 279 (2004) 9417-9423
53. O'Neil J., et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to γ-secretase inhibitors. J. Exp. Med. 204 (2007) 1813-1824
54. Wu G., Hubbard E.J., Kitajewski J.K., and Greenwald I. Evidence for functional and physical association between Caenorhabditis elegans SEL-10, a Cdc4p-related protein, and SEL-12 presenilin. Proc. Natl. Acad. Sci. USA 95 (1998) 15787-15791
55. Wu G., et al. SEL-10 is an inhibitor of notch signaling that targets notch for ubiquitin-mediated protein degradation. Mol. Cell. Biol. 21 (2001) 7403-7415
56. Tetzlaff M.T., et al. Defective cardiovascular development and elevated cyclin E and Notch proteins in mice lacking the Fbw7 F-box protein. Proc. Natl. Acad. Sci. USA 101 (2004) 3338-3345
57. Punga T., Bengoechea-Alonso M.T., and Ericsson J. Phosphorylation and ubiquitination of the transcription factor sterol regulatory element-binding protein-1 in response to DNA binding. J. Biol. Chem. 281 (2006) 25278-25286
58. Sundqvist A., Bengoechea-Alonso M.T., Ye X., Lukiyanchuk V., Jin J., Harper J.W., and Ericsson J. Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCF(Fbw7). Cell Metab. 1 (2005) 379-391
59. Olson B.L., Hock M.B., Ekholm-Reed S., Wohlschlegel J.A., Dev K.K., Kralli A., and Reed S.I. SCFCdc4 acts antagonistically to the PGC-1α transcriptional coactivator by targeting it for ubiquitin-mediated proteolysis. Genes Dev. 22 (2008) 252-264
60. Wu R.C., Feng Q., Lonard D.M., and O'Malley B.W. SRC-3 coactivator functional lifetime is regulated by a phospho-dependent ubiquitin time clock. Cell 129 (2007) 1125-1140
61. Li J., et al. SEL-10 interacts with presenilin 1, facilitates its ubiquitination, and alters A-β peptide production. J. Neurochem. 82 (2002) 1540-1548
62. Mao J.H., et al. Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature 432 (2004) 775-779
63. Yeh E.S., Lew B.O., and Means A.R. The loss of PIN1 deregulates cyclin E and sensitizes mouse embryo fibroblasts to genomic instability. J. Biol. Chem. 281 (2006) 241-245
64. Reed S.I. Cooperation between different Cdc4/Fbw7 isoforms may be associated with 2-step inactivation of SCF(Cdc4) targets. Cell Cycle 5 (2006) 1923-1924
65. Popov N., et al. The ubiquitin-specific protease USP28 is required for MYC stability. Nat. Cell Biol. 9 (2007) 765-774
66. Popov N., Herold S., Llamazares M., Schulein C., and Eilers M. Fbw7 and Usp28 regulate myc protein stability in response to DNA damage. Cell Cycle 6 (2007) 2327-2331
67. Kimura T., Gotoh M., Nakamura Y., and Arakawa H. hCDC4b, a regulator of cyclin E, as a direct transcriptional target of p53. Cancer Sci. 94 (2003) 431-436
68. Kominami K., Ochotorena I., and Toda T. Two F-box/WD-repeat proteins Pop1 and Pop2 form hetero- and homo-complexes together with cullin-1 in the fission yeast SCF (Skp1-Cullin-1-F-box) ubiquitin ligase. Genes Cells 3 (1998) 721-735
69. Seibert V., Prohl C., Schoultz I., Rhee E., Lopez R., Abderazzaq K., Zhou C., and Wolf D.A. Combinatorial diversity of fission yeast SCF ubiquitin ligases by homo- and heterooligomeric assemblies of the F-box proteins Pop1p and Pop2p. BMC Biochem. 3 (2002) 22
70. Tang X., et al. Suprafacial orientation of the SCFCdc4 dimer accommodates multiple geometries for substrate ubiquitination. Cell 129 (2007) 1165-1176
71. Welcker M., and Clurman B.E. Fbw7/hCDC4 dimerization regulates its substrate interactions. Cell Div. 2 (2007) 7
72. Akhoondi S., et al. FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res. 67 (2007) 9006-9012
73. Knuutila S., et al. DNA copy number losses in human neoplasms. Am. J. Pathol. 155 (1999) 683-694
74. Rhodes D.R., et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 9 (2007) 166-180
75. Knudson Jr. A.G. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. USA 68 (1971) 820-823
76. Bahram F., von der Lehr N., Cetinkaya C., and Larsson L.G. c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood 95 (2000) 2104-2110
77. Gregory M.A., Qi Y., and Hann S.R. Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. J. Biol. Chem. 278 (2003) 51606-51612
78. Oster S.K., Ho C.S., Soucie E.L., and Penn L.Z. The myc oncogene: MarvelouslY Complex. Adv. Cancer Res. 84 (2002) 81-154
79. Malyukova A., et al. The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling. Cancer Res. 67 (2007) 5611-5616
80. Weng A.P., et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306 (2004) 269-271
81. Minella A.C., Welcker M., and Clurman B.E. Ras activity regulates cyclin E degradation by the Fbw7 pathway. Proc. Natl. Acad. Sci. USA 102 (2005) 9649-9654
82. Welcker M., and Clurman B.E. The SV40 large T antigen contains a decoy phosphodegron that mediates its interactions with Fbw7/hCdc4. J. Biol. Chem. 280 (2005) 7654-7658
83. Perez-Losada J., Mao J.H., and Balmain A. Control of genomic instability and epithelial tumor development by the p53-Fbxw7/Cdc4 pathway. Cancer Res. 65 (2005) 6488-6492
84. Rajagopalan H., Jallepalli P.V., Rago C., Velculescu V.E., Kinzler K.W., Vogelstein B., and Lengauer C. Inactivation of hCDC4 can cause chromosomal instability. Nature 428 (2004) 77-81
85. Felsher D.W., and Bishop J.M. Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc. Natl. Acad. Sci. USA 96 (1999) 3940-3944
86. Ekholm-Reed S., Spruck C.H., Sangfelt O., van Drogen F., Mueller-Holzner E., Widschwendter M., Zetterberg A., and Reed S.I. Mutation of hCDC4 leads to cell cycle deregulation of cyclin E in cancer. Cancer Res. 64 (2004) 795-800
87. Keck J.M., Summers M.K., Tedesco D., Ekholm-Reed S., Chuang L.C., Jackson P.K., and Reed S.I. Cyclin E overexpression impairs progression through mitosis by inhibiting APC(Cdh1). J. Cell Biol. 178 (2007) 371-385
88. Welcker M., Orian A., Jin J., Grim J.E., Harper J.W., Eisenman R.N., and Clurman B.E. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc. Natl. Acad. Sci. USA 101 (2004) 9085-9090
89. Johnson R., Spiegelman B., Hanahan D., and Wisdom R. Cellular transformation and malignancy induced by ras require c-jun. Mol. Cell. Biol. 16 (1996) 4504-4511
90. Dievart A., Beaulieu N., and Jolicoeur P. Involvement of Notch1 in the development of mouse mammary tumors. Oncogene 18 (1999) 5973-5981
91. Hallahan A.R., et al. The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res. 64 (2004) 7794-7800
92. Klinakis A., Szabolcs M., Politi K., Kiaris H., Artavanis-Tsakonas S., and Efstratiadis A. Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in mice. Proc. Natl. Acad. Sci. USA 103 (2006) 9262-9267
93. Lin Y.W., Nichols R.A., Letterio J.J., and Aplan P.D. Notch1 mutations are important for leukemic transformation in murine models of precursor-T leukemia/lymphoma. Blood 107 (2006) 2540-2543
94. O'Neil J., et al. Activating Notch1 mutations in mouse models of T-ALL. Blood 107 (2006) 781-785
95. Gridley T. Kick it up a Notch: NOTCH1 activation in T-ALL. Cancer Cell 6 (2004) 431-432
96. Weng A.P., et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev. 20 (2006) 2096-2109
97. Yang Y.A., Han W.F., Morin P.J., Chrest F.J., and Pizer E.S. Activation of fatty acid synthesis during neoplastic transformation: role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Exp. Cell Res. 279 (2002) 80-90